Connect with us

Technology

DR. DAVID AMRON TESTIFIES BEFORE U.S. SENATE SPECIAL COMMITTEE ON AGING ON AI-ENABLED FRAUD TARGETING OLDER AMERICANS

Published

on

Internationally Recognized Lipedema Surgeon Shares Firsthand Experience with AI-Generated Medical Impersonation and Calls for Stronger Protections for Patients

LOS ANGELES, Aug. 3, 2026 /PRNewswire/ — On Wednesday, July 29, 2026, Dr. David Amron, Founder and Medical Director of The Roxbury Institute and Founder and Chair of The Lipedema Society, appeared before the U.S. Senate Special Committee on Aging to testify during “The AI Deception Machine: Deepfakes, Chatbots, and the New Frontier of Senior Fraud.”

Dr. Amron joined Senate Special Committee on Aging Chairman Rick Scott, Ranking Member Kirsten Gillibrand, Senators Mark Kelly and Tommy Tuberville, other lawmakers, consumer advocates, cybersecurity experts, banking leaders, and a fraud victim to examine the growing threat artificial intelligence poses to older Americans.

Dr. Amron was invited to Washington to testify after his name, image, voice, and professional reputation were unlawfully used in a sophisticated AI-generated medical impersonation scam to promote a fraudulent so-called “miracle” lipedema cream. His appearance before the Committee focused on raising awareness, bringing the issue directly to Congress, and helping advance legislation to create stronger protections for patients, physicians, older Americans, and other consumers.

The deceptive advertisements incorporated authentic footage from Dr. Amron’s YouTube channel that was manipulated to make it appear he had endorsed the product. The scammers also created an entirely AI-generated likeness, image, and voice of his colleague, Dr. Karen Herbst, Head of Research and Director of Diagnostic and Preventative Medicine at The Roxbury Institute. AI-generated celebrity images and stolen media logos were also used to create polished advertisements that appeared entirely legitimate.

Several individuals purchased the fraudulent product before learning the advertisements were fabricated, including one of Dr. Amron’s own patients.

The scam first came to light after concerned patients began contacting The Roxbury Institute with questions about the advertisements. As soon as the fraud was identified, Dr. Amron and his team began investigating and reporting the coordinated scam to Facebook, the fraudulent social media accounts responsible for publishing the advertisements, the domain registrars hosting the websites, Google Ads, and the major search engines directing consumers to the scam.

Despite persistent reporting efforts, each time one version was removed, another quickly appeared, highlighting the limitations of existing reporting systems in combating coordinated AI-enabled fraud.

After exhausting every available reporting mechanism, Dr. Amron brought national attention to the issue through NBC’s TODAY Show, helping expose the sophisticated scam and educate consumers about the growing dangers of AI-generated medical impersonation.

The bipartisan Senate hearing examined how artificial intelligence is increasingly being exploited through deepfakes, voice cloning, chatbots, and other emerging technologies to target older Americans with sophisticated scams. Throughout the hearing, lawmakers and expert witnesses emphasized the urgent need for stronger consumer protections, greater accountability, improved public education, and enhanced collaboration between government and the private sector.

“What disturbed me most was not that someone had misused my image. It was knowing that scammers had used my name and reputation to deceive the very people I have dedicated my career to helping,” said Dr. David Amron. “This problem is no longer theoretical. It is happening right now, and the consequences for patient safety, medical ethics, and the integrity of healthcare information are profound.”

During his testimony, Dr. Amron warned that the consequences of AI-generated medical fraud extend far beyond financial loss. Patients may delay legitimate medical care for a progressive disease like lipedema, rely on products falsely presented as physician-endorsed, and allow their condition to worsen, and allow their condition to worsen.

Perhaps most damaging, these scams erode the trust patients place in their physicians, leaving them uncertain about whom they can trust for legitimate medical guidance.

Dr. Amron also urged Congress to improve accountability for those who create and distribute AI-generated impersonation scams and ensure that laws keep pace with rapidly advancing technology.

His testimony underscored the growing threat AI-enabled fraud poses not only to older Americans, but also to patient safety, medical ethics, and public trust in healthcare. By sharing his firsthand experience, Dr. Amron hopes to help drive meaningful policy solutions that better protect patients and consumers from increasingly sophisticated AI-generated deception.

For interviews or media inquiries, please contact:
Natalia Grazziani
Grazziani Communications
natalia@grazzianicommunications.com
323-646-1581

About The Roxbury Institute

The Roxbury Institute, founded by Dr. David Amron in Los Angeles, is a nationally recognized multidisciplinary center specializing in advanced treatment for individuals with fat disorders and those seeking aesthetic and medical dermatology care. Built on clinical excellence and innovative research, the Institute has offices in Salt Lake City and Tucson. Its specialties include advanced lipedema treatment, liposculpture, and revision liposuction, supported by divisions in Research, Diagnosis and Prevention, Advanced Lipedema Treatment, and Aesthetic Medicine and Dermatology. These programs address complex and often misunderstood conditions while advancing scientific knowledge, setting national standards of care, and providing evidence-based, patient-focused treatment. From diagnosis through long-term care, The Roxbury Institute reflects a commitment to enduring patient outcomes and comprehensive support.

To learn more, please visit: www.theroxburyinstitute.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-david-amron-testifies-before-us-senate-special-committee-on-aging-on-ai-enabled-fraud-targeting-older-americans-302840440.html

SOURCE The Roxbury Institute

Continue Reading

Technology

Jamie Knight Named Chief Studios Officer to Accelerate Studio Innovation and Growth

Published

on

By

Knight to Build on the Global Studio Foundation Established by Jean Venneman, Who Will Retire After More Than 30 Years in Gaming

LAS VEGAS, Sept. 21, 2026 /PRNewswire/ — IGT announced today that, Jamie Knight will assume the role of Chief Studios Officer on Jan. 1, 2027, succeeding Jean Venneman, who will retire at the end of 2026 following more than 30 years in gaming. Knight will build on the strong foundation established under Venneman’s leadership and lead IGT’s continued studio investments, driving innovation across game design, content development and studio operations.

Knight brings two decades of experience across the industry’s largest suppliers, with deep expertise in translating creative vision into player-favorite content. Having begun her career as a creative, she understands the collaborative process required to transform original concepts into successful products, a perspective that will inform her leadership of studio operations.

Jean Venneman, who will retire on December 31, 2026, began her career at IGT in the early 1990s and went on to hold senior leadership roles across product development, licensing, technology and operations before rejoining IGT in 2024. Since returning, she has rebuilt the company’s global studio operations from the ground up. Under her leadership, she assembled and empowered a world-class studio team with more than 1,200 employees, established shared best practices across studio cultures and created the operational and creative foundation that positions IGT and Everi for accelerated growth.

“Jean’s leadership created the foundation for this next phase of growth,” said Hector Fernandez, IGT CEO. “She brought together talented teams, strengthened how our studios operate and raised the bar for creative and operational excellence. We are deeply grateful for everything she has contributed to our organization and our industry. Jamie’s combination of creative instinct, studio leadership and focus on innovation in design and math will build on that momentum and unlock new possibilities across our combined studio organization.”

As Chief Studios Officer, Knight will establish clear priorities for studio teams, drive innovation in game mechanics and mathematical modeling, and create an environment where creative talent can do exceptional work. Her vision centers on delivering the most dynamic and engaging content that meets the evolving demands of players and operators globally.

“I’m energized to lead our studio teams and build on the strong foundation in place,” said Jamie Knight, incoming Chief Studios Officer. “Together with our talented teams across IGT and Everi, we’ll push the boundaries of what’s possible in game design, content strategy, and math innovation to deliver world-class experiences on the floor.”

“Returning to this organization and helping strengthen our global studio organization has been a meaningful way to close my career,” said Jean Venneman, Chief Studios Officer. “I am incredibly proud of our studio teams and the foundation we have created. I am confident Jamie will carry that momentum forward and help unlock the next phase of our growth.”

For more information, follow IGT on Facebook and LinkedIn or watch IGT videos on YouTube.

About IGT
IGT is a leading global provider of gaming, digital and financial technology solutions, formed through the combination of International Game Technology PLC’s Gaming & Digital Business and Everi Holdings Inc. IGT and Everi’s offering spans gaming machines, game content and systems, iGaming, sports betting, cash access, loyalty and player engagement solutions, enabling it to deliver integrated, customer-centric experiences across land-based and digital environments. Organized into Gaming, Digital and FinTech business units, the organization drives innovation, efficiency and value for casino, digital and hospitality operators worldwide. The company is headquartered in Las Vegas.

Contact:
Phil O’Shaughnessy, Global Communications
Toll free in U.S./Canada +1 (844) IGT-7452
Outside U.S./Canada +1 (775) 448-0257

© 2026 IGT

The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.

View original content to download multimedia:https://www.prnewswire.com/news-releases/jamie-knight-named-chief-studios-officer-to-accelerate-studio-innovation-and-growth-302884034.html

SOURCE IGT

Continue Reading

Technology

Lysander Announces Cash Distributions for the Lysander-Canso ActivETFs

Published

on

By

TORONTO, Sept. 21, 2026 /CNW/ — Lysander Funds Limited (“Lysander”) announces the September 2026 cash distributions for each of Lysander-Canso Corporate Treasury ActivETF, Lysander-Canso Floating Rate ActivETF and Lysander-Canso Credit Income ActivETF (TSX: LYCT) (TSX: LYFR) and (TSX: PBY) respectively (each, an “ETF” and collectively, the “ETFs”). Unitholders of record of each ETF at the close of business on the Distribution Record Date will receive a cash distribution based on the number of units held in the amount indicated below, payable on or before the Payment Date.

ETF

Distribution per unit

Distribution Record Date

Payment Date

Lysander-Canso Corporate Treasury ActivETF

$0.0128

September 29, 2026

October 13, 2026

Lysander-Canso Floating Rate ActivETF

$0.0193

September 29, 2026

October 13, 2026

Lysander-Canso Credit Income ActivETF

$0.0417

September 29, 2026

October 13, 2026

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. 

®Lysander Funds is a registered trademark of Lysander Funds Limited.

SOURCE Lysander Funds Limited

Continue Reading

Technology

DAXIO Sets Three-Year Public-Market Pathway Towards a $1 Billion Valuation

Published

on

By

Founder-owned trade show and commercial-technology company combines 12 specialist US events, proprietary DealConnect technology, $35.7 million in annual commercial capacity and a high-margin AI-powered operating model

WEST PALM BEACH, Fla., Sept. 21, 2026 /PRNewswire-PRWeb/ — DAXIO today set out its three-year pathway towards a public-market listing and a $1 billion enterprise valuation.

“With 12 specialist events, proprietary DealConnect technology and $35.7 million in annual commercial capacity, DAXIO has a defined three-year pathway to a $1 billion valuation and public-market listing.” — Dawn Barclay-Ross, Founder and Chief Executive, DAXIO

Founded and wholly owned by international trade show organizer Dawn Barclay-Ross, DAXIO has established a portfolio of 12 specialist US events supported by proprietary DealConnect technology, qualified Hosted Buyer programmes and a portfolio-wide AI operating system.

The portfolio contains approximately $35.7 million in maximum annual commercial inventory capacity: $32.2 million in stand inventory and $3.54 million in sponsorship, advertising and Thought Leadership opportunities.

At 35%, 60% and 85% inventory realization, annual portfolio revenues are approximately $12.5 million, $21.4 million and $30.4 million respectively.

DAXIO’s current cost model indicates the potential for portfolio contribution margins above 90% at scale, reflecting its AI-powered infrastructure, centralized technology and capital-efficient operating structure.

“The next billion-dollar exhibition business will not resemble the last generation of exhibition groups,” said Barclay-Ross, Founder and Chief Executive of DAXIO.

“It will combine deep industry expertise with proprietary technology, intelligent automation and disciplined commercial execution. It will be faster, leaner and more accountable for the business value created at every event. That is DAXIO.”

Twelve events. One scalable commercial platform.

DAXIO’s 2027 portfolio comprises InfraBuild, PowerXpo, EnerWasteXpo, AgriTechXpo, BioGenomic Health Expo, Advanced Medical Device Show, NextGen MedTech Xpo, InsureCap, SmartMfg, AerospaceXpo, DefenseXpo and TalentTech.

Together, the events establish DAXIO across infrastructure, energy, environmental services, agriculture, healthcare, medical technology, insurance, manufacturing, aerospace, defense and workforce technology.

The portfolio has capacity for up to 5,856 stand-equivalent positions across the full commercially deployable event footprint.

Its multi-sector structure creates diversified revenue opportunities through stand sales, sponsorship, advertising, Thought Leadership, commercial partnerships and technology.

DealConnect moves the model beyond networking

DAXIO’s principal technology asset is DealConnect, created by Barclay-Ross to move business-event matchmaking beyond profile-swiping, unqualified introductions and chance encounters.

DealConnect assesses more than 500 data points across capability, compliance and financial dimensions to identify stronger-fit commercial opportunities during DAXIO events.

It operates alongside DAXIO’s qualified Hosted Buyer programmes. Approved buyers with purchasing responsibility and confirmed budgets may receive flights and hotel accommodation in return for agreeing to attend scheduled meetings with exhibitors during the event.

“Attendance is not the commercial outcome,” Barclay-Ross said. “The outcome is whether the right organizations meet, whether the opportunity is credible and whether that conversation can progress into business. DealConnect is designed around that standard.”

A three-year pathway to public markets

DAXIO’s public-market pathway is structured around five measurable drivers:

Converting revenue across the existing 12-event portfolioExtending the portfolio into further specialist and international marketsEstablishing recurring commercial revenues through DealConnectPreserving high margins through AI-powered executionAchieving institutional standards of governance, reporting and financial control 

Barclay-Ross has applied 25 years of international trade show and business-development experience to create an integrated exhibitions and commercial-technology company without the inherited cost base of a conventional exhibition group.

DAXIO is wholly founder-owned and independent of private-equity ownership, institutional exhibition groups and external corporate control.

“The first 12 events give DAXIO significant commercial scale. DealConnect creates proprietary technology value. Our AI operating system provides the execution capacity to operate across multiple specialist markets while protecting margin,” Barclay-Ross said.

“The pathway is already defined: convert the existing inventory, extend the portfolio, establish recurring technology income and enter the public markets as a high-growth exhibitions and commercial-technology company.

“The platform exists. The commercial capacity is quantified. The margin model is compelling. The route is repeatable. DAXIO’s pathway to a $1 billion valuation is underway.”

Strategic capital window closes September 25

DAXIO’s current $200,000 strategic-capital participation window closes on Friday, September 25, 2026.

The capital will be deployed directly into revenue-generating activity across the existing portfolio, including exhibitor and sponsor acquisition, qualified-buyer development, commercial marketing, technology deployment and sales execution.

The current financing provides a time-limited opportunity for eligible investors to participate at the beginning of DAXIO’s three-year public-market pathway.

Confidential company and investment information is available to eligible investors and professional advisers directly from DAXIO.

About DAXIO

DAXIO is a founder-owned, independent trade show and commercial-technology company headquartered in Florida.

Its portfolio comprises 12 specialist US business events supported by proprietary DealConnect technology, qualified Hosted Buyer programmes and an AI-powered operating infrastructure.

DAXIO is executing a three-year pathway towards a $1 billion enterprise valuation and public-market listing.

Media and investor enquiries

Dawn Barclay-Ross
Founder and Chief Executive
DAXIO
dawn@infrabuildXpo.com
+1 561 785 3120

Media Contact

Dawn Barclay-Ross, Capital Connect International Events Inc dba DAXIO, 1 5617853120, dawn@capitalconnectevents.com, https://www.infrabuildxpo.com/

View original content to download multimedia:https://www.prweb.com/releases/daxio-sets-three-year-public-market-pathway-towards-a-1-billion-valuation-302884930.html

SOURCE Capital Connect International Events Inc dba DAXIO

Continue Reading

Trending